ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Inc., founded in 1993, is a biopharmaceutical company based in San Diego, California, known for its focus on developing innovative medicines to address unmet medical needs in central nervous system disorders. As of the latest update, the CEO is Steve Davis, who has been leading the company to further its commitment to improving the lives of patients through novel treatments. ACADIA's flagship product, NUPLAZID (pimavanserin), was the first FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis and has marked a significant milestone in the company's history. With a strong pipeline of drug candidates, ACADIA continues to advance its research in neurological and mental health conditions. Recent financial reports indicate that the company is driven by both revenue growth from its existing products and strategic investment in its R&D efforts to expand its therapeutic portfolio.